Log in

NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

$1.66
-0.12 (-6.74 %)
(As of 02/28/2020 06:42 AM ET)
Today's Range
$1.62
Now: $1.66
$1.80
50-Day Range
$1.66
MA: $2.34
$2.81
52-Week Range
$1.62
Now: $1.66
$6.09
Volume4.64 million shs
Average Volume3.89 million shs
Market Capitalization$450.73 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.65 million
Book Value$0.03 per share

Profitability

Net Income$-176,150,000.00
Net Margins-354.79%

Miscellaneous

Employees241
Market Cap$450.73 million
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.


TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) issued its earnings results on Thursday, February, 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The firm had revenue of $15.90 million for the quarter, compared to analysts' expectations of $12.82 million. TherapeuticsMD had a negative net margin of 354.79% and a negative return on equity of 1,170.63%. The business's revenue was up 212.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) earnings per share. View TherapeuticsMD's Earnings History.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for TherapeuticsMD.

What guidance has TherapeuticsMD issued on next quarter's earnings?

TherapeuticsMD updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90-110 million, compared to the consensus revenue estimate of $100.15 million.

What price target have analysts set for TXMD?

9 Wall Street analysts have issued 1-year price objectives for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate TherapeuticsMD's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 442.2% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

What is the consensus analysts' recommendation for TherapeuticsMD?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Has TherapeuticsMD been receiving favorable news coverage?

Media coverage about TXMD stock has trended positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. TherapeuticsMD earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for TherapeuticsMD.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 90,930,000 shares, an increase of 6.5% from the January 30th total of 85,400,000 shares. Based on an average daily volume of 3,530,000 shares, the short-interest ratio is presently 25.8 days. Currently, 38.4% of the company's shares are short sold. View TherapeuticsMD's Current Options Chain.

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
  • Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (6.52%), Bank of New York Mellon Corp (4.84%), Franklin Resources Inc. (3.50%), State Street Corp (2.04%), Bamco Inc. NY (1.41%) and Stifel Financial Corp (1.11%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

Which major investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, FMR LLC, Franklin Resources Inc., Sanders Morris Harris LLC, SG Americas Securities LLC, Raymond James & Associates and First Eagle Investment Management LLC. View Insider Buying and Selling for TherapeuticsMD.

Which major investors are buying TherapeuticsMD stock?

TXMD stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Marshall Wace North America L.P., State Street Corp, Knights of Columbus Asset Advisors LLC, Goldman Sachs Group Inc., Hawk Ridge Capital Management LP and Stifel Financial Corp. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $1.66.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $450.73 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  347 (Thanks for Voting!)
Underperform Votes:  303 (Thanks for Voting!)
Total Votes:  650
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel